Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506135 | 0.76 | TSHR (0.43) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL6910772 | 0.76 | TSHR (0.36) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| Hydrogen Peroxide SCHEMBL14993963 | 0.75 | — | — | |
| Bicarbonate SCHEMBL2938234 | 0.74 | TSHR (0.33) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL16382875 | 0.74 | TSHR (0.40) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL6937150 | 0.74 | TSHR (0.40) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL6200830 | 0.72 | TSHR (0.38) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL18970410 | 0.72 | KDM4E (0.42) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL83786 | 0.72 | TSHR (0.55) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL8356639 | 0.72 | ALDH1A1 (0.34) | TSHRALDH1A1CYP2D6CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | DFH THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9868758-B2 | Betulinic proline imidazole derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2018-01-16 | — | — | US | disclosed |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-05-11 | — | — | US | disclosed |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2017-05-11 | — | — | US | disclosed |
| US-9637516-B2 | Betulinic acid proline derivatives as HIV inhibitors | HETERO RESEARCH FOUNDATION (IN) | 2017-05-02 | — | — | US | disclosed |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-01-12 | — | — | US | disclosed |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-11-26 | — | — | US | disclosed |
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | TSHR 4804/4885ALDH1A1 4432/4885CYP2D6 3427/4885 |
| US-20170129916-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PREP | TSHR 4703/4885ALDH1A1 4180/4885CYP2D6 4099/4885 |
| US-20170008921-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | TSHR 4301/4885ALDH1A1 3909/4885CYP2D6 2984/4885 |
| US-20180215780-A1 | C-3 NOVEL TRITERPENONE WITH C-28 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | ERG28, CCR3, ACBD3 | TSHR 4376/4885ALDH1A1 3486/4885CYP2D6 2358/4885 |
| US-20170129917-A1 | NOVEL BETULINIC PROLINE IMIDAZOLE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, IMPA1 | TSHR 4740/4885ALDH1A1 4100/4885CYP2D6 4315/4885 |
| US-20150337004-A1 | NOVEL BETULINIC ACID PROLINE DERIVATIVES AS HIV INHIBITORS | BET1, PRR12, PELP1 | TSHR 4748/4885ALDH1A1 4297/4885CYP2D6 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.